PT Diagnos Laboratorium Utama Tbk

dgns

Overview

DGNS Overview

PT Diagnos Laboratorium Utama Tbk is an Indonesia-based company that is engaged in providing health services using laboratories. The Company’s scope of activities also includes private clinical activities. Its products and services include clinical pathology laboratory tests, anatomical pathology laboratory tests, genomics laboratory tests, homecare health tests, corporate health tests and Covid-19 tests. Its clinical pathology laboratory provides services ranging from molecular examinations to support more treatment. Its clinical pathology laboratory provides services for examination of hematology, hemostasis, clinical chemistry, urinalysis, biomolecular, immunology and microbiology. The services provided at the genetic laboratory are non-invasive prenatal testing (NIPT), preimplantation genetic testing for aneuploidy (PGT-A) services, and preimplantation genetic testing for monogenic diseases (PGT-M) services. Its homecare health services provide health checks that are done at home.

51015ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: DGNS

Development
Market Cap.
IDR 392.50Billion

~$24.75M USD

Industry
Healthcare Providers
Sub-Industry
Healthcare Providers
Sector
Healthcare

Valuation

DGNS Valuation Metrics

314

IDR

Closing Price on 2024-04-05

Price to Equity

-38.69

P/E

At -38.69x P/E TTM, DGNS.JK is trading at a discount to its peers in the Healthcare Equipment & Providers sector.

Price to Book

1.96

P/B

At 1.96x P/B TTM, DGNS.JK is trading in line with its peers in the Healthcare Equipment & Providers sector.

Price to Sales

2.51

P/S

At 2.51x P/S TTM, DGNS.JK is trading at a discount to its peers in the Healthcare Equipment & Providers sector.

Valuing PT Diagnos Laboratorium Utama Tbk based on its trailing twelve months (TTM) valuation metrics against its peers in the Healthcare Equipment & Providers sector

Historical Price to Earnings

Other Valuation Metrics

Valuing PT Diagnos Laboratorium Utama Tbk relative to other stocks in the Healthcare Equipment & Providers sector

Price/Cash Flow
20.13x
Price/Forward Earnings
-
Enterprise Value/Revenue
2.62x
Enterprise Value/EBITDA
965.73x
PEG Ratio
0.14x

Analyst Ratings

No analyst ratings available yet.

Last closing: IDR3142024-04-05
IDR 8.89

Considerably Lower Intrinsic Value: Analyst's intrinsic value is of DGNS is IDR9, which is 96% lower than DGNS's last closing price of IDR314 (as of 2024-04-05).

Valuation Recap of DGNS stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of -38.69x is below the ID market average of 8.22x and is trading at a discount to peers in the Healthcare Equipment & Providers sector (23.78x). In fact, less than 25% of its peers trade at a lower P/E ratio than DGNS.●●●
Max 3
High
The P/B ratio is calculated by dividing the market price of a company's stock by its book value per share (BVPS). It measures the company's stock value relative to its assets minus liabilities. A P/B ratio of 1.96x is similar to the peers average of 1.80x in the Healthcare Equipment & Providers sector.
Max 3
Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 2.51x is similar to the peers average of 3.00x in the Healthcare Equipment & Providers sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of DGNS's valuation relative to its current sales and future earnings growth.
Max 2
Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. DGNS's P/CF ratio of 20.13x is considered a relatively high ratio by analysts.
Max 2
Low
The Enterprise Value/Revenue ratio (EV/R) is calculated by dividing the enterprise value of a company by its revenue. It measures the company's enterprise value relative to its revenue. It is an indicator of how much it costs to buy the company's revenue; the lower the ratio, the cheaper the company's revenue. DGNS's EV/R ratio of 2.62x is considered fairly underpriced by the market The average EV/R ratio for the Healthcare Equipment & Providers sector is 2.98x. ●●
Max 3
Medium
Considerably Lower Intrinsic Value: Analyst's intrinsic value is of DGNS is IDR 8.89, which is 96% lower than DGNS's last closing price of IDR 314.00.
Max 3

Peers

DGNS Peers and Comparison

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk68.46T27.18T 30.31T 2.96T 23.123.31
MIKAPT Mitra Keluarga Karyasehat Tbk.39.22T7.11T 4.13T 0.95T 41.297.01
SILOPT Siloam International Hospitals Tbk.32.40T10.75T 10.83T 1.11T 29.294.28
SRAJSejahteraraya Anugrahjaya Tbk20.58T5.62T 2.35T -0.05T -433.0911.10
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk20.25T3.75T 3.61T 0.97T 20.865.94
HEALPT Medikaloka Hermina Tbk.19.03T8.52T 5.54T 0.48T 39.485.15
PRAYPT Famon Awal Bros Sedaya Tbk9.42T4.42T 1.70T 0.18T 53.643.42
TSPCTempo Scan Pacific Tbk9.09T11.31T 12.93T 1.41T 6.431.18
SOHOPT Soho Global Health Tbk6.24T4.67T 7.91T 0.34T 18.422.45
OMEDPT Jayamas Medica Industri Tbk5.33T2.46T 1.63T 0.22T 23.782.50
Competitiveness Recap of DGNS stock
WeightNotesScore
High
At a market cap of IDR 392.50 billion, DGNS.JK ranks 10 in Market Cap out of 10 companies in the Healthcare sector.
Max 2
High
At a PE of -38.69, DGNS.JK ranks 9 out of 10 companies in the Healthcare sector for P/E value. The average PE is -23.93 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. In this regard, it trails behind sector leaders such as PT Famon Awal Bros Sedaya Tbk (53.64) in the Healthcare sector.
Max 2
Medium
At a PE of -38.69, DGNS.JK is trading at a lower PE than that of its subsector peers in Healthcare Equipment & Providers (median of 23.78). A lower P/E value presents a potential value opportunity, but it might also indicate that the company is facing headwinds in its business.
Max 2
Medium
At a revenue of IDR 0.16 trillion, DGNS.JK ranks 10 in Revenue out of 10 companies in the Healthcare sector.
Max 2
Medium
At a profit of -IDR 0.01 trillion, DGNS.JK ranks 9 in Profit out of 10 companies in the Healthcare sector.
Max 2

Future

Future Growth of DGNS

Growth Forecasts

No data available

Sector Benchmark

Healthcare Equipment & Providers companies in Indonesia are growing at a projected rate of 23.68% against the IDX average of +12.0%.

Healthcare Equipment & Providers sector overview
No data is available for DGNS at the moment.
Future growth prospect of DGNS
WeightNotesScore
High
DGNS's projected growth rate of 23.68% is above the ID market average of 11.98%.●●●
Max 3
High
The Healthcare Equipment & Providers sub-sector is projected to grow revenue by 22.97% in 2024. This number is higher than the previous year 2023's growth rate of 9.96%. This bodes well for DGNS's revenue growth prospects in the next 2 years. ●●●
Max 3
Medium
The Healthcare Equipment & Providers sub-sector is projected to increase earnings by 29.75% in 2024. This number is higher than the previous year 2023's EPS growth of 9.77%. This bodes well for DGNS's earnings growth prospects in the next 2 years. ●●●
Max 3
Medium
DGNS and its peers in the Healthcare Equipment & Providers sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a fruitful year heading into 2024. Specifically, earnings are projected to increase by 16.30% in 2024 while revenue growth is projected to increase by 17.10%. These macroeconomic trends will likely be a tailwind for DGNS's earnings growth prospects in the next 2 years. ●●
Max 3
Loading...
Loading...

Management

Executive Management

President Director

Ir. Mesha Rizal Sini15.2 years
Renobulan Rizal Sini Suheimi
Director
Dennis Jacobus
Director
Fergus Richard
Director
Dilly Dwiasri
Director
NamePositionShares%
No data is available for DGNS at the moment.
Expressed in millions IDR, unless otherwise stated

Ownership

DGNS Ownership

Others
20%
Insiders
80%
Institutions
0%
NameNumber of SharesOwnership (%)Value
Pt Bundamedik515,000,00041.2161.71B
Pt Bunda Investama Indonesia485,000,00038.8152.29B
Public (Scripless)250,000,0002078.50B
No data is available for DGNS at the moment.